China Life Sciences - January 2013


In This Issue:

Investor Q&A; Key Regulatory Issues for Strategic Life Sciences Partnerships in China; Compulsory Patent Licensing in China; and New Developments on the “Patentable Subject Matter” Requirement of U.S. Patent Law.

Excerpt from Investor Q&A -

Dr. Dan Zhang has more than ten years of drug development experience. He is the Chief Executive Officer of Fountain Medical Development, a full-service clinical CRO company based in South East Asia and China. Previously, Dr. Zhang was the head of clinical development and global safety assessment at Sigma-Tau Research Inc., a Vice President at the Quintiles Transnational Corp., and the Chairman of the Board at Quintiles Medical Development (Shanghai) Company Ltd.

Please see full issue below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Morrison & Foerster LLP | Attorney Advertising

Written by:


Morrison & Foerster LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.